Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
Direct Access to DoD Decision-Makers and Researchers
MHSRS provides direct access to organizations seeking military partnerships and connects companies with key funding organizations. Tivic鈥檚 President of Biopharma and Chief Operating Officer, Michael Handley, met with key members of the Biomedical Advanced Research and Development Authority (BARDA), the Armed Forces Radiobiology Research Institute (AFRRI) and the Medical CBRN Defense Consortium (MCDC) to discuss potential pathways to deploy Entolimod as a military countermeasure.
BARDA鈥檚 mission is to develop medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. AFRRI鈥檚 mission is to defend the Nation from nuclear and radiological threats through research, leadership, training, and education. The MCDC was formed in response to the US Government鈥檚 expressed interest to engage and fund advanced development efforts to support the Department of Defense鈥檚 (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.
鈥淚t was an honor to contribute to the vital conversations that were focused generally on radiation medical countermeasures, and specifically on our lead clinical product candidate, Entolimod, which has the potential to protect the warfighter in the instance that they are exposed to radiation,鈥� said Handley.
Representatives from Tivic joined global thought leaders, military leaders and researchers to share insights, explore collaborative opportunities, and present ongoing research intended to improve health outcomes for warfighters exposed to radiation in the field.
About MHSRS
MHSRS serves as a dynamic platform for the exchange of research findings across multiple disciplines, including combat casualty care, medical countermeasures, infectious disease, and mental health. The symposium fosters collaboration among business leaders, scientists, clinicians, and policymakers, ensuring innovations reach those who serve as quickly and effectively as possible.
About Tivic
Tivic鈥檚 dual platform utilizes the body鈥檚 biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system.
Tivic鈥檚 biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod鈩� for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development.
Tivic鈥檚 bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic鈥檚 approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit:
Forward-Looking Statements
This press release may contain 鈥渇orward-looking statements鈥� that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渟eek,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渢arget,鈥� 鈥渁im,鈥� 鈥渟hould,鈥� 鈥渨ill鈥� 鈥渨ould,鈥� or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.鈥檚 current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities, as well as interactions with governmental agencies, such as BARDA, the AFRRI and the MCDC; changes to the company鈥檚 relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company鈥檚 future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company鈥檚 business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company鈥檚 need for, and ability to secure when needed, additional working capital; the company鈥檚 ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health鈥檚 filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 鈥淩isk Factors," as well as the company鈥檚 subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com:
Investor Contact:
Hanover International, Inc.
[email protected]
Media Contact
[email protected]
Source: Tivic Health Systems, Inc.
